Last reviewed · How we verify
Simvastatin plus ticagrelor
Simvastatin reduces cholesterol synthesis while ticagrelor inhibits platelet aggregation, combining lipid-lowering and antiplatelet effects for cardiovascular protection.
Simvastatin reduces cholesterol synthesis while ticagrelor inhibits platelet aggregation, combining lipid-lowering and antiplatelet effects for cardiovascular protection. Used for Acute coronary syndrome with elevated cholesterol, Secondary prevention of cardiovascular events in high-risk patients.
At a glance
| Generic name | Simvastatin plus ticagrelor |
|---|---|
| Also known as | Zocor & Brilinta |
| Sponsor | Federal University of São Paulo |
| Drug class | Statin plus P2Y12 receptor antagonist combination |
| Target | HMG-CoA reductase; P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Simvastatin is an HMG-CoA reductase inhibitor that decreases LDL cholesterol and reduces atherosclerotic plaque formation. Ticagrelor is a P2Y12 receptor antagonist that prevents platelet activation and thrombosis. Together, they address both lipid management and thrombotic risk in cardiovascular disease.
Approved indications
- Acute coronary syndrome with elevated cholesterol
- Secondary prevention of cardiovascular events in high-risk patients
Common side effects
- Bleeding
- Muscle pain or myopathy
- Bradycardia
- Dyspnea
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Role of Immune Responses After Acute Myocardial Infarction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Simvastatin plus ticagrelor CI brief — competitive landscape report
- Simvastatin plus ticagrelor updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI